Karlsson Mikael C, Gonzalez Santiago F, Welin Josefin, Fuxe Jonas
Department of Microbiology, Tumor Biology and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland.
Mol Oncol. 2017 Jul;11(7):781-791. doi: 10.1002/1878-0261.12092. Epub 2017 Jun 26.
It was already in the 18th century when the French surgeon LeDran first noted that breast cancer patients with spread of tumor cells to their axillary lymph nodes had a drastically worse prognosis than patients without spread (LeDran et al., ). Since then, metastatic spread of cancer cells to regional lymph nodes has been established as the most important prognostic factor in many types of cancer (Carter et al., ; Elston and Ellis, ). However, despite its clinical importance, lymph metastasis remains an underexplored area of tumor biology. Fundamental questions, such as when, how, and perhaps most importantly, why tumor cells disseminate through the lymphatic system, remain largely unanswered. Accordingly, no treatment strategies exist that specifically target lymph metastasis. The identification of epithelial-mesenchymal transition (EMT) as a mechanism, which allows cancer cells to dedifferentiate and acquire enhanced migratory and invasive properties, has been a game changer in cancer research. Conceptually, EMT provides an explanation for why epithelial cancers with poor differentiation status are generally more aggressive and prone to metastasize than more differentiated cancers. Inflammatory cytokines, such as TGF-β, which are produced and secreted by tumor-infiltrating immune cells, are potent inducers of EMT. Thus, reactivation of EMT also links cancer-related inflammation to invasive and metastatic disease. Recently, we found that breast cancer cells undergoing TGF-β-induced EMT acquire properties of immune cells allowing them to disseminate in a targeted fashion through the lymphatic system similar to activated dendritic cells during inflammation. Here, we review our current understanding of the mechanisms by which cancer cells spread through the lymphatic system and the links to inflammation and the immune system. We also emphasize how imaging techniques have the potential to further expand our knowledge of the mechanisms of lymph metastasis, and how lymph nodes serve as an interface between cancer and the immune system.
早在18世纪,法国外科医生勒德兰就首次指出,肿瘤细胞扩散至腋窝淋巴结的乳腺癌患者的预后比未扩散的患者要差得多(勒德兰等人)。从那时起,癌细胞向区域淋巴结的转移扩散已被确立为多种癌症中最重要的预后因素(卡特等人;埃尔斯顿和埃利斯)。然而,尽管其具有临床重要性,但淋巴转移仍是肿瘤生物学中一个未被充分探索的领域。一些基本问题,比如肿瘤细胞何时、如何以及或许最重要的是为何通过淋巴系统扩散,在很大程度上仍未得到解答。因此,不存在专门针对淋巴转移的治疗策略。上皮-间质转化(EMT)作为一种机制被发现,它能使癌细胞去分化并获得更强的迁移和侵袭特性,这在癌症研究中带来了重大变革。从概念上讲,EMT解释了为何分化程度低的上皮癌通常比分化程度高的癌症更具侵袭性且更容易转移。肿瘤浸润免疫细胞产生和分泌的炎性细胞因子,如转化生长因子-β(TGF-β),是EMT的强效诱导剂。因此,EMT的重新激活也将癌症相关炎症与侵袭性和转移性疾病联系了起来。最近,我们发现经历TGF-β诱导的EMT的乳腺癌细胞获得了免疫细胞的特性,使其能够像炎症期间活化的树突状细胞一样通过淋巴系统以靶向方式扩散。在此,我们综述了目前对癌细胞通过淋巴系统扩散的机制以及与炎症和免疫系统联系的理解。我们还强调了成像技术如何有可能进一步扩展我们对淋巴转移机制的认识,以及淋巴结如何作为癌症与免疫系统之间的界面。